Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIVASTIGMINE vs ROMIDEPSIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIVASTIGMINE vs ROMIDEPSIN: Safety Overview

Metric RIVASTIGMINE ROMIDEPSIN
Total FAERS Reports 9,123 1,282
Deaths Reported 2,232 343
Death Rate 24.5% 26.8%
Hospitalizations 2,716 458
Average Patient Age 80.0 yrs 64.7 yrs
% Female Patients 59.5% 46.5%
FDA Approval Date Apr 21, 2000 Mar 13, 2020
Manufacturer Novartis Pharmaceuticals Corporation Fresenius Kabi USA, LLC
Route TRANSDERMAL N/A
Marketing Status Discontinued Prescription